PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

ganciclovir Side Effects

The reactions most often reported to the FDA for ganciclovir (also sold as Cytovene), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

9,877
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2001 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of ganciclovir come from 9,877 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 9,877 reports to the FDA Adverse Event Reporting System (FAERS) for ganciclovir (Cytovene): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

9,877

Reports Mentioning Death

3,034

30.7% of reports — not proof the medicine caused the death

Hospitalizations

3,970

40.2% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

CYTOMEGALOVIRUS INFECTION
1,170
DRUG RESISTANCE
653
PYREXIA
590
NEUTROPENIA
503
PANCYTOPENIA
503
DIARRHOEA
434
CYTOMEGALOVIRUS VIRAEMIA
413
PNEUMONIA
411
SEPSIS
400
MULTIPLE ORGAN DYSFUNCTION SYNDROME
379
RESPIRATORY FAILURE
378
CYTOMEGALOVIRUS INFECTION REACTIVATION
355
THROMBOCYTOPENIA
351
LEUKOPENIA
331
CONDITION AGGRAVATED
320
RENAL IMPAIRMENT
313
ACUTE KIDNEY INJURY
305

Who Reports Side Effects

Gender Distribution

Female 3,635 (42%)
Male 4,937 (57%)
Unknown 80

Age Distribution

0-17 1,560 (20%)
18-44 2,261 (29%)
45-64 2,676 (34%)
65-74 976 (12%)
75+ 359 (5%)

Reporting Trend by Year

2001 2025

Reactions in Death Reports

Top reactions reported in 3,034 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
CYTOMEGALOVIRUS INFECTION 362
MULTIPLE ORGAN DYSFUNCTION SYNDROME 333
SEPSIS 276
RESPIRATORY FAILURE 254
PANCYTOPENIA 251
PNEUMONIA 230
PYREXIA 229
SEPTIC SHOCK 202
POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER 166
DEATH 156
EPSTEIN-BARR VIRUS INFECTION 154
GRAFT VERSUS HOST DISEASE 149
RENAL FAILURE 145
CYTOMEGALOVIRUS INFECTION REACTIVATION 140
ACUTE KIDNEY INJURY 139
NEUTROPENIA 139
THROMBOCYTOPENIA 137

Reactions in Hospitalization Reports

Top reactions in 3,970 reports where hospitalization was an outcome.

Reaction Reports
CYTOMEGALOVIRUS INFECTION 555
PYREXIA 384
DIARRHOEA 275
PANCYTOPENIA 244
PNEUMONIA 229
RESPIRATORY FAILURE 223
NEUTROPENIA 201
SEPSIS 200
ACUTE KIDNEY INJURY 196
THROMBOCYTOPENIA 193
CYTOMEGALOVIRUS INFECTION REACTIVATION 189
LEUKOPENIA 167
CONDITION AGGRAVATED 166
RENAL FAILURE 164
DRUG RESISTANCE 160
ANAEMIA 159
MULTIPLE ORGAN DYSFUNCTION SYNDROME 152
RENAL IMPAIRMENT 151

Compare ganciclovir vs acyclovir →

What the FAERS Data Reveals About ganciclovir Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 9,877 voluntary reports linked to ganciclovir and its brand equivalents (Cytovene), spanning 2001 through 2025. Of those, 3,034 (30.7%) listed death as an outcome and 3,970 (40.2%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 42% were female and 57% male; age distribution skews toward 45-64, with 2,676 reports in that bracket. The single most reported reaction is cytomegalovirus infection with 1,170 submissions, followed by drug resistance and pyrexia.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.